Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accelerated Approval: Mend, Don't End, Pazdur Tells ODAC After Avastin

Executive Summary

Genentech's Avastin may not have produced a storybook ending in metastatic breast cancer, but it still serves as an example of how the accelerated approval process can work

You may also be interested in...



FDA Asks ODAC To Ponder Shift Away From Single-Arm Studies

At its Feb. 8 meeting on issues surrounding confirmatory post-marketing studies, the Oncologic Drugs Advisory Committee will discuss whether and when randomized studies should be required to secure accelerated approval.

FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less

A Senate Appropriations Committee-approved funding package would provide the Center for Drug Evaluation and Research with $5 million more than requested by the Obama administration

FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less

A Senate Appropriations Committee-approved funding package would provide the Center for Drug Evaluation and Research with $5 million more than requested by the Obama administration

Related Content

Topics

UsernamePublicRestriction

Register

PS052442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel